English
English
Patentler ve İlaçlar
FarmaPatent
 

 

 

 

Imatinib


 

Imatinib

CAS Registry Number 

152459-95-5

 

ATC Code

L01XE01

 

 

Therapeutic class

Antineoplastic

Imatinib (originally STI571) is a drug used to treat certain cancers. It is marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia/Latin America) as its mesylate salt, imatinib mesilate (INN).

It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and some other diseases. By 2011, Gleevec has been FDA approved to treat ten different cancers.

In January 2012, three of the developers of imatinib were awarded the Japan Prize for their work.

Imatinib was developed by rational drug design.

Gleevec received FDA approval in May 2001. Gleevec also holds the record for the drug with the fastest approval time by the FDA.

 

 

Dosage Form

Administration  Route

Active Substance

Unit Dosage

TABLET

ORAL

IMATINIB MESYLATE

100, 400 MG

 

 

Original Brand Name

JANUVIA (MSD)

Excipients

TABLET Core:

Microcrystalline cellulose, Crospovidone, Hypromellose, Magnesium stearate, Silica colloidal anhydrous

Coating:

Hypromellose, Macrogol, Talc, Iron oxide red, Iron oxide yellow

 

 

US Basic Patent

EP Basic Patent

TR Basic Patent

TR Secondary Patents

First EU Authorisation

Country

5521184

04.07.2015

0564409 B1

20.06.2016

-

 

SEARCH!

21.06.2001

Switzerland